Norethindrone Acetate/Ethinyl Estradiol
Also called Norethisterone Acetate/ethinylestradiol in India, Australia, the UK and most countries outside the US.
Norethindrone Acetate/Ethinyl Estradiol comes in 2 pill versions in our database, in 2 strengths, from 2 manufacturers. Check the imprint to tell them apart.
Norethindrone Acetate/Ethinyl Estradiol pill images
1 mg / 5 mcg 1 pill
1 mg / 20 mcg 1 pill
What is Norethindrone Acetate/Ethinyl Estradiol used for?
Norethindrone Acetate/Ethinyl Estradiol is used for menopause symptoms and osteoporosis (weak bones).
- Medicine type
- Progestin hormone; estrogen hormone
Official uses from the US prescribing label
femhrt is indicated in women with an intact uterus for the:
- Treatment of moderate to severe vasomotor symptoms associated with the menopause.
- Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis. Non-estrogen medications should be carefully considered.
The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women.
Risk factors for osteoporosis include low bone mineral density, low estrogen levels, family history of osteoporosis, previous fracture, small frame (low BMI), light skin color, smoking, and alcohol intake. Response to therapy can be predicted by pre-treatment serum estradiol, and can be assessed during treatment by measuring biochemical markers of bone formation/resorption, and/or bone mineral density.
Estrogen therapy reduces bone resorption and retards or halts postmenopausal bone loss. Studies have shown a risk ratio of about 0.4 for hip and wrist fractures in women whose estrogen therapy was begun within a few years of menopause, compared to women taking calcium and vitamin D alone. Studies also suggest that estrogen reduces the rate of vertebral fractures. Even when started as late as 6 years after menopause, estrogen reduces further loss of bone mass for as long as treatment is continued. When estrogen therapy is discontinued, bone mass declines at a rate comparable to the immediate postmenopausal period.
Data from the Women's Health Initiative study showed that use of estrogen-plus-progestin (dose equivalent to 0.625 mg CE and 2.5 mg MPA) resulted in about 5 less hip fractures per 10,000 women-years, compared to use of placebo (risk ratio about 0.66).
From the FDA-approved label on DailyMed (published Sep 01, 2010).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.